Back

Basilea partner starts phase 2 pediatric Cresemba study in Japan

Verifying
  • Asahi Kasei Therapeutics started a phase 2 Japanese study of pediatric Cresemba.
  • Cresemba recorded $782 million in global sales from April 2025 through March 2026.
  • Cresemba is approved for children in the US, Canada, Europe and China.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.